

A large, teal-colored curved graphic element that starts near the top center and curves downwards and to the right, ending near the middle of the page.

Area Prescribing Committee / Interface Interim Update - Luforbec[®]

Please direct queries to your ICB medicines
optimisation pharmacist

or e-mail nnicb-nn.nottsapc@nhs.net

A large, yellow-colored curved graphic element that starts near the bottom left corner and curves upwards and to the right, ending near the bottom center of the page.

Luforbec[®] - background

- The Nottinghamshire APC [Asthma in Adults](#) guideline was updated in March 2023.
- Fostair[®] inhaler (MDI) preparations were replaced by Luforbec[®] inhaler (MDI) as the first-line cost effective ICS/LAMA MDI/pMDI option.
- Fostair[®] MART was replaced with Luforbec[®] MART.
- Both inhalers contain the **SAME** active ingredients (beclometasone/formoterol) at the **SAME** strength and in the **SAME** type of device.
- Nottingham University Hospitals and Sherwood Forest Hospitals have already implemented the switch to Luforbec[®] from Fostair[®].
- It has now been agreed in Nottinghamshire that **ALL** patients, where appropriate, will be changed from Fostair[®] inhaler (MDI) to Luforbec[®] inhaler (MDI) in line with the local guidelines.



Primary Care Actions

- A switch cover letter was sent to practices via TeamNet <https://teamnet.clarity.co.uk/Library/ViewItem/57f22198-61b8-45c3-b75d-b0dd00cf4711>
- This change is supported by the ICS Respiratory Group, which includes Respiratory Specialists from NUH and SFH, Community services, Primary Care and patient representation and is endorsed by the Nottingham and Nottinghamshire ICB.
- Patients should be advised to continue to use their Fostair[®] inhaler until it is finished. A Luforbec[®] inhaler will be issued at the next repeat prescription request.
- Patients should be reminded to return used inhalers to their community pharmacy for safe disposal.

Primary Care Actions

- To support practices, a “Prescriber Pack” has been produced in consultation with the ICS Respiratory Group, which includes:
 - Switch Practice “How-To” Guide
 - Community Pharmacy Template Letter
 - Patient Template Letter
 - Patient Information Letter
- These documents are available on Medicines Optimisation Website

<https://www.nottinghamshiremedicinesmanagement.nhs.uk/policies-and-documents/medicines-management-policies/prescribing-policies/>

Making this switch will save up to £3.4 million across the county, which can then be reinvested into our NHS.

Further Information

If you would like further information on this change, or would like to discuss how your practice can best implement this change, please contact your designated ICB Medicines Optimisation Pharmacist



- [Nottinghamshire Area Prescribing Committee Website](#)
- [Nottinghamshire Joint Formulary Website](#)

- [Nottinghamshire Area Prescribing Committee Bulletins](#)
- [Nottinghamshire Area Prescribing Committee Meeting Minutes](#)

- [ICB Preferred Prescribing List](#)
- [Guide to setting up SystemOne formulary in GP practices](#)